How Non-Psychoactive Cannabinoids Like CBD Fight Cancer in Lab and Animal Studies
CBD and other non-psychoactive cannabinoids inhibited tumor growth, invasion, and metastasis across multiple aggressive cancer types in animal models, and enhanced the effectiveness of standard chemotherapy drugs.
Quick Facts
What This Study Found
This review examined how non-psychoactive cannabinoids, particularly CBD, affect cancer cells through mechanisms that do not require activation of CB1 or CB2 cannabinoid receptors.
In animal models, CBD inhibited the progression of glioblastoma, breast, lung, prostate, and colon cancers. The mechanisms included triggering autophagy (cellular self-digestion) and apoptosis (programmed cell death), inhibiting tumor cell invasion and metastasis, reducing blood vessel formation that feeds tumors, and limiting the stem-like potential of cancer cells.
Particularly notable was CBD's ability to enhance the activity of first-line chemotherapy agents commonly used in cancer treatment, suggesting potential as a combination therapy.
Key Numbers
Cancer types with CBD efficacy in animal models: glioblastoma, breast, lung, prostate, colon; mechanisms: autophagy, apoptosis, anti-invasion, anti-metastasis, anti-angiogenesis, cancer stem cell inhibition
How They Did This
Review of preclinical literature examining non-psychoactive cannabinoids (primarily CBD) in cancer models. Focused on mechanisms including autophagy, apoptosis, invasion, metastasis, angiogenesis, and cancer stem cell inhibition.
Why This Research Matters
Non-psychoactive cannabinoids offer potential antitumor activity without the high associated with THC. The ability to enhance standard chemotherapy is particularly promising, as it could improve treatment outcomes without adding psychoactive side effects.
The Bigger Picture
While THC is primarily known for palliative effects in cancer (nausea, pain), non-psychoactive cannabinoids may have direct antitumor activity. However, these findings remain preclinical, and human clinical trials are needed before drawing therapeutic conclusions.
What This Study Doesn't Tell Us
All evidence is from cell culture and animal models. No human clinical trial data for CBD as an antitumor agent. Doses used in preclinical studies may not be achievable in humans. The translation gap between animal cancer models and human cancer is well-documented.
Questions This Raises
- ?Will CBD's antitumor effects translate to human cancers?
- ?What doses are needed?
- ?Can CBD meaningfully enhance chemotherapy in clinical settings?
- ?Are there cancer types where CBD might interfere with treatment?
Trust & Context
- Key Stat:
- CBD inhibited 5 cancer types in animal models and enhanced chemotherapy
- Evidence Grade:
- Comprehensive review of preclinical evidence. Promising mechanisms identified across multiple cancer types, but no human clinical data for antitumor effects.
- Study Age:
- Published in 2015. Some early-phase clinical trials of CBD in cancer have since been initiated.
- Original Title:
- The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.
- Published In:
- Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 10(2), 255-67 (2015)
- Database ID:
- RTHC-01014
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can CBD cure cancer?
There is no evidence that CBD cures cancer in humans. This review summarized animal and cell studies showing CBD can inhibit tumor growth through multiple mechanisms, but human clinical trials are needed before any therapeutic claims can be made.
How is this different from using marijuana for cancer symptoms?
THC is used to manage cancer symptoms like nausea and pain (palliative care). This research examines whether non-psychoactive cannabinoids like CBD have direct antitumor effects, meaning they might fight the cancer itself, not just the symptoms. This remains unproven in humans.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01014APA
McAllister, Sean D; Soroceanu, Liliana; Desprez, Pierre-Yves. (2015). The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 10(2), 255-67. https://doi.org/10.1007/s11481-015-9608-y
MLA
McAllister, Sean D, et al. "The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.." Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2015. https://doi.org/10.1007/s11481-015-9608-y
RethinkTHC
RethinkTHC Research Database. "The Antitumor Activity of Plant-Derived Non-Psychoactive Can..." RTHC-01014. Retrieved from https://rethinkthc.com/research/mcallister-2015-the-antitumor-activity-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.